注：截至本公告披露日，因仁筵信息债转股增资变动之工商变更登记尚未完成，使得如上 列示认缴注册资本与工商登记显示金额存在差异，以下同。 证券代码：688607 证券简称：康众医疗 公告编号：2025-032 江苏康众数字医疗科技股份有限公司 关于对外投资暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、关联交易概述 为持续推进公司战略转型升级，打造经营业务第二增长曲线、聚焦 AI 赋能 基层医疗、助力公司经营业务稳步发展，公司拟使用自有资金 2,000.00 万元人 民币以增资形式参股仁筵信息，对应标的公司新增注册资本 24.1476 万元，本 次增资完成后，公司将持有仁筵信息 6.67%股权。具体情况如下： 单位：元/人民币 江苏康众数字医疗科技股份有限公司（以下简称"康众医疗"或"公 司"）拟使用自有资金2,000.00万元人民币以增资形式参股上海仁筵信 息科技有限公司（以下简称"仁筵信息"或"标的公司"），对应标的公司 新增注册资本24.1476万元，本次增资完成后，公司将持有仁筵信 ...

证券代码：688607 证券简称：康众医疗 公告编号：2025-033 江苏康众数字医疗科技股份有限公司 关于计提信用减值损失的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、计提减值准备情况的概述 根据《企业会计准则》和江苏康众数字医疗科技股份有限公司（以下简称"公 司"）会计政策的相关规定，为客观、公允地反映公司的财务状况及经营成果， 公司及合并报表范围内的子公司对截至2025年6月30日公司应收账款及其他应收 款进行了减值测试，公司计提信用减值损失合计876.68万元。具体情况如下表所 示： | 项目 | 2025年半年度计提金额（万元） | | --- | --- | | 信用减值损失 | 876.68 | | 其中：应收账款坏账损失 | 839.28 | | 其他应收款坏账损失 | 37.39 | 二、计提信用减值损失事项的具体说明 公司以预期信用损失为基础，同时结合个别认定法，对应收账款和其他应收 款进行减值测试。在资产负债表日公司依据相关会计政策和会计估计测算表明其 中发生了减值的，公司按规定计提减 ...

Group 1 - The core point of the article is that Kangzhong Medical (688607) is making a strategic move to enhance its business by investing in AI-enabled grassroots healthcare through a capital increase in Shanghai Renyan Information Technology Co., Ltd. [1] - The company plans to invest 20 million yuan to acquire a 6.67% stake in Renyan Information, indicating a focus on developing a second growth curve for its operations [1]

Core Viewpoint - The medical device sector experienced a decline of 2.16% on August 14, with Lide Man leading the drop, while the Shanghai Composite Index fell by 0.46% and the Shenzhen Component Index decreased by 0.87% [1]. Group 1: Market Performance - The medical device sector's overall performance was negative, with a notable decline in key stocks [1]. - Lide Man's stock price fell by 11.21%, closing at 10.06, with a trading volume of 1.06 million shares [2]. - The sector saw a net outflow of 1.517 billion yuan from major funds, while retail investors contributed a net inflow of 1.269 billion yuan [2]. Group 2: Top Gainers - Botao Biological (688767) saw a significant increase of 19.99%, closing at 45.13 with a trading volume of 104,300 shares and a transaction value of 436 million yuan [1]. - Toukeng Life (300642) rose by 10.85%, closing at 19.10 with a trading volume of 310,100 shares [1]. - Jimin Health (603222) increased by 10.05%, closing at 8.10 with a trading volume of 944,800 shares [1]. Group 3: Notable Decliners - Lide Man (300289) led the decline with a drop of 11.21%, closing at 10.06 with a trading volume of 1.0605 million shares [2]. - Zhonghong Medical (300981) fell by 9.91%, closing at 16.00 with a trading volume of 261,300 shares [2]. - Haitai New Light (688677) decreased by 7.93%, closing at 45.30 with a trading volume of 49,100 shares [2].

Group 1 - Shanghai Haiwang Hezong Private Fund Partnership (Limited Partnership) has undergone a business change, adding Kangxi Communication, Anji Technology, and Aojie Technology as shareholders [1] - The enterprise was established in March 2025 with a registered capital of 2.11 billion yuan [1] - The business scope includes private equity investment, investment management, and asset management activities [1]

Meeting Overview - The first extraordinary general meeting of Jiangsu Kangzhong Digital Medical Technology Co., Ltd. was held on August 1, 2025, at the company's conference room in Suzhou Industrial Park [2][4] - All 9 current directors and 3 supervisors attended the meeting, along with the board secretary and other senior executives [4] Voting and Resolutions - The meeting adopted a combination of on-site and online voting methods, and was presided over by Chairman Jianqiang Liu [4] - All proposed resolutions were passed, including the cancellation of the supervisory board and amendments to the company's articles of association, shareholder meeting rules, board meeting rules, independent director work system, and cumulative voting implementation details [5][6] Legal Compliance - The meeting's procedures, attendance, and voting methods were confirmed to comply with the Company Law, Securities Law, and the company's own regulations by the witnessing lawyers from Zhonglun Law Firm [6]

证券代码：688607 证券简称：康众医疗 公告编号：2025-031 江苏康众数字医疗科技股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 1、本次股东大会采用现场投票和网络投票相结合的方式进行表决； 2、本次会议由公司董事会召集，董事长 JIANQIANG LIU（刘建强）先生主持； 3、本次会议的召集召开程序、表决方式和表决程序符合《公司法》及《公司章 程》的规定，会议合法有效。 （五） 公司董事和董事会秘书的出席情况 3、 董事会秘书尹晟先生出席了本次会议；其他高管的列席本次会议。 二、 议案审议情况 （一） 股东会召开的时间：2025 年 8 月 1 日 （二） 股东会召开的地点：苏州工业园区星湖街 218 号生物纳米园 B3 楼 501 室公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 42 | ...

2025 年第一次临时股东会的 法律意见书 北京市中伦律师事务所 关于江苏康众数字医疗科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受江苏康众数字医疗科技股 份有限公司（以下简称"公司"）的委托，就公司 2025 年第一次临时股东会（以 下简称"本次股东会"）召开的有关事宜，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）和上海证券交易所发 布的《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等现 行有效的法律、法规、规范性文件及《江苏康众数字医疗科技股份有限公司章程》 （以下简称"《公司章程》"）、《江苏康众数字医疗科技股份有限公司股东会 议事规则》（以下简称"《股东会议事规则》"）的有关规定，出具本法律意见 书。 致：江苏康众数字医疗科技股份有限公司 为出具本法律意见书，本所律师审查了公司本次股东会的有关文件和材料。 本所律师得到公司如下保证，即其已提供了本所律师认为出具本法律意见书所必 需的材料，所提供的原始材料、副本、复印件等材料、口头证言均符合真实、准 ...

Core Viewpoint - The recent financing net purchase of 15.76 million yuan for Kangzhong Medical has sparked significant interest among investors, highlighting a shift in A-share financing behavior from aggressive strategies to more cautious, incremental investments [1][3]. Group 1: Financing Dynamics - Kangzhong Medical ranked 480th in financing net purchases, indicating a unique position among A-share stocks, where many investors are curious about its appeal despite its relatively low financing amount compared to major players like Ningde Times and Moutai [3][4]. - The stock's financing ranking suggests that it is neither a top performer nor completely ignored, making it a potential target for retail investors who perceive it as a safer option [4][5]. Group 2: Company Overview - Kangzhong Medical specializes in medical imaging equipment, with a reported revenue of over 300 million yuan and a net profit of over 40 million yuan, but its non-recurring net profit has declined by 20% year-on-year, raising concerns about its financial health [4][5]. - The company has a high gross margin of 50%, but it has consistently negative cash flow, which may deter institutional investors from engaging with it [4][5]. Group 3: Investor Behavior - The financing net purchase of 15.76 million yuan reflects the presence of three types of retail investors: value investors who misinterpret the company's financials, gamblers relying on potentially false insider information, and technical analysts who may misread market signals [6][7][8]. - Retail investors often engage in "bottom-fishing" strategies, buying stocks that have significantly declined, which can lead to further losses if the stock continues to underperform [11][13]. Group 4: Market Trends - The current market environment shows that 90% of financing positions are held by retail investors, with institutional investors dominating the top-performing stocks, indicating a challenging landscape for retail investors [11][12]. - The trend of "small but beautiful" stocks like Kangzhong Medical is fading, as market dynamics shift towards larger, more established companies, leaving smaller stocks vulnerable to neglect [12]. Group 5: Conclusion - The financing activity surrounding Kangzhong Medical serves as a cautionary tale for retail investors, emphasizing the importance of understanding market dynamics and the risks associated with investing in lower-ranked stocks [14].

Group 1 - The company will hold its first extraordinary general meeting of shareholders in 2025 on August 1, 2025, with specific procedures outlined for attendance and voting [1][4][5] - Shareholders must present identification and relevant documents to confirm their attendance and voting rights [2][3] - The meeting will include a series of agenda items, including the election of voting and monitoring members, and the discussion and voting on various proposals [8] Group 2 - Proposal one involves the cancellation of the supervisory board and the revision of the company's articles of association, transferring the supervisory functions to the audit committee of the board [6][7] - Proposal two focuses on revising the rules governing shareholder meetings to enhance operational efficiency and protect shareholder rights [9] - Proposal three aims to revise the rules governing board meetings to promote sustainable development and operational efficiency [10] - Proposal four seeks to enhance the efficiency and independence of independent directors through revisions to the independent director working system [12] - Proposal five is about revising the implementation details of the cumulative voting system to improve decision-making efficiency at shareholder meetings [12]